Therefore, diminishing the CCL2 and CCR2 interaction through the mTOR cascade may reduce TAMs recruitment and chemotaxis, subsequently promoting the anti-tumor effect of CD8+ T cells in TME. The gene discussed is CCL2; the disease is neoplasm.